miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma

(2013) Sweta Rani et al.   CANCER BIOLOGY & THERAPY

Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility

(2013) Tsang-Chih Kuo et al.   JOURNAL OF CLINICAL INVESTIGATION

Upregulation of miR-150* and miR-630 Induces Apoptosis in Pancreatic Cancer Cells by Targeting IGF-1R

(2013) Lulu Farhana et al.   PLoS One

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

(2012) Nancy U. Lin et al.   BREAST CANCER RESEARCH AND TREATMENT

Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

(2012) A Gallardo et al.   BRITISH JOURNAL OF CANCER

miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours

(2012) Francesca Biagioni et al.   EMBO Molecular Medicine

Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines

(2012) Fiona O’Neill et al.   Molecular Cancer

Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes

(2012) Claire Corcoran et al.   PLoS One

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

(2011) Leiping Wang et al.   BMC CANCER

IGF1R-Targeted Therapy and Its Enhancement of Doxorubicin Chemosensitivity in Human Osteosarcoma Cell Lines

(2011) Frederick Luk et al.   CANCER INVESTIGATION

Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells

(2011) Y Huang et al.   CELL DEATH AND DIFFERENTIATION

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells

(2010) B. C. Browne et al.   ANNALS OF ONCOLOGY

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

(2010) Anne M. Friel et al.   BREAST CANCER RESEARCH AND TREATMENT

miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death

(2010) L. Galluzzi et al.   CANCER RESEARCH

Intracellular and Extracellular MicroRNAs in Breast Cancer

(2010) C. Corcoran et al.   CLINICAL CHEMISTRY

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

(2010) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo

(2010) Yin-He Wang et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

(2010) N. A. O'Brien et al.   MOLECULAR CANCER THERAPEUTICS

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

HER-2 Signaling and Inhibition in Breast Cancer

(2009) B. Browne et al.   CURRENT CANCER DRUG TARGETS